New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line

European Journal of Clinical Investigation, Supplement

Volumn 30, Issue 3, 2000, Pages 76-82

  Fassnacht, M ^a,c   Hahner, S ^a   Beuschlein, F ^b   Klink, A ^b   Reincke, M ^b   Allolio, B ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Adrenostatic compounds; Cushing's syndrome

Indexed keywords

AMINOGLUTETHIMIDE; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CORTICOTROPIN; CORTICOTROPIN RECEPTOR; CYCLIC AMP; ETOMIDATE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; HYDROXYPROGESTERONE; MESSENGER RNA; METYRAPONE; PRASTERONE SULFATE; STEROID 11BETA MONOOXYGENASE;

ADRENAL CORTEX CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CUSHING SYNDROME; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEROIDOGENESIS;

EID: 0034484013     PISSN: 0960135X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.0300s3076.x     Document Type: Conference Paper

References (48)

1. Inhibitors of P450-dependent steroid biosynthesis: From research to medical treatment
2. Effects of amino-glutethimide on adrenal function in man
3. Effects of aminoglutethimide upon adrenal function and cortisol metabolism in Cushing's syndrome
4. Aminoglutethimide in the treatment of Cushing's syndrome
5. Aminoglutethimide: Review of pharmacology and clinical use
6. Adrenostatic treatment of ACTH-dependent Cushing syndrome using metyrapone and aminoglutethimide
7. Effects of metyrapone on pregnenolone biosynthesis and on cholesterol-cytochrome P-450 interaction in adrenal
8. Structural studies of metyrapone: A potent inhibitor of cytochrome P- 450
9. Adrenal cortical 11b-hydroxylase and side-chain cleavage enzymes. Requirement for the A- or B-pyridyl ring in metyrapone for inhibition
10. Direct in vitro inhibition of adrenal steroidogenesis by etomidate
11. A simple in vitro approach to the estimation of the biopotency of drugs affecting adrenal steroidogenesis
12. On the assessment of the in vitro biopotency and site(s) of action of drugs affecting adrenal steroidogenesis
13. Effects of etomidate on steroid biosynthesis in subcellular fractions of bovine adrenals
14. Inhibition of adrenal steroidogenesis by the anesthetic etomidate
15. Direct inhibitory effect of etomidate on corticosteroid secretion in human pathologic adrenocortical cells
16. Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis
17. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors
18. Adrenocortical suppression by a single induction dose of etomidate
19. Effect of a single bolus of etomidate upon eight major corticosteroid hormones and plasma ACTH
20. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome
21. Infusion of low dose etomidate: Correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects
22. Medical treatment of Cushing's syndrome
23. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis
24. Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids
25. ACTH induces up-regulation of ACTH receptor mRNA in mouse and human adrenocortical cell lines
26. The NCI-H295 cell line: A pluripotent model for human adrenocortical studies
27. Adrenal incidentalomas: A manifestation of the metabolic syndrome?
28. The cloning of a family of genes that encode the melanocortin receptors
29. Primary structure and expression of a functional human glucocorticoid receptor cDNA
30. Glucocorticoids enhance corticotropin receptor mRNA levels in ovine adrenocortical cells
31. Plasma metyrapone, adrenocorticotropic hormone, cortisol, and deoxycortisol levels. Sequential changes during oral and intravenous metyrapone administration
32. Aminoglutethimide in advanced breast cancer: Plasma levels and clinical results after low and high doses
33. Indicative therapeutic and toxic drug concentration in plasma: A tabulation
34. Primary therapy for Cushing's disease with metyrapone
35. The medical treatment of Cushing's syndrome
36. Up regulation of corticotrophin receptors by ACTH1-24 in normal and hypophysectomized rabbits
37. Corticotropin positively regulates its own receptors and cAMP response in cultured bovine adrenal cells
38. Regulation of corticotropin receptor number and messenger RNA in cultured human adrenocortical cells by corticotropin and angiotensin II
39. Regulation of bovine adrenal cell corticotropin receptor mRNA levels by corticotropin (ACTH) and angiotensin-II (A-II)
40. Regulation of ACTH receptor mRNA and binding sites by ACTH and angiotensin II in cultured human and bovine adrenal fasciculata cells
41. Adrenocorticotropic hormone (ACTH) increases the expression of its own receptor gene
42. Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: Correlation with P450scc expression
43. Localization and expression of adrenocorticotropic hormone receptor mRNA in normal and neoplastic human adrenal cortex
44. Glucocorticoid enhancement of adrenocorticotropin-induced 3′,5′-cyclic adenosine monophosphate production by cultured ovine adrenocortical cells
45. Glucocorticoid enhancement of glucocorticoid production by cultured ovine adrenocortical cells
46. Mechanism of glucocorticoid enhancement of the responsiveness of ovine adrenocortical cells to adrenocorticotropin
47. Glucocorticoids potentiate effect of ACTH on cortisol secretion in isolated perfused guinea pig adrenal glands
48. Characterization of the human ACTH receptor gene and in vitro expression